{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:14:58Z","timestamp":1789784098528,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T00:00:00Z","timestamp":1475884800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Astellas Pharma Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10096-016-2802-x","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T19:31:24Z","timestamp":1475868684000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-493X","authenticated-orcid":false,"given":"C.","family":"Feh\u00e9r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"M\u00fa\u00f1ez Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Merino Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Delgado-Iribarren Garcia-Campero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salavert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maseda Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"D\u00edaz-Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,8]]},"reference":[{"issue":"Suppl 2","key":"2802_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12418","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1\u201326. doi: 10.1111\/1469-0691.12418","journal-title":"Clin Microbiol Infect"},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(11)61514-6.WEB-ONLY","volume":"12","author":"O Cornely","year":"2012","unstructured":"Cornely O, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K et al (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet 12:281\u2013289. doi: 10.1016\/S0140-6736(11)61514-6.WEB-ONLY","journal-title":"Lancet"},{"key":"2802_CR3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane K, Weiss K, Lentnek A, Golan Y et al (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422\u2013431","journal-title":"N Engl J Med"},{"key":"2802_CR4","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/jac\/dku261","volume":"69","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IAO (2014) Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 69:2892\u20132900. doi: 10.1093\/jac\/dku261","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"2802_CR5","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/cid\/cis462","volume":"55","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL (2012) Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 55(Suppl 2):S154\u2013S161. doi: 10.1093\/cid\/cis462","journal-title":"Clin Infect Dis"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cid\/cis339","volume":"55","author":"EJC Goldstein","year":"2012","unstructured":"Goldstein EJC, Babakhani F, Citron DM (2012) Antimicrobial activities of fidaxomicin. Clin Infect Dis 55:143\u2013148. doi: 10.1093\/cid\/cis339","journal-title":"Clin Infect Dis"},{"key":"2802_CR7","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cis338","volume":"55","author":"TJ Louie","year":"2012","unstructured":"Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M et al (2012) Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile Infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55:S132\u2013S142. doi: 10.1093\/cid\/cis338","journal-title":"Clin Infect Dis"},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/cis453","volume":"55","author":"F Babakhani","year":"2012","unstructured":"Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL (2012) Fidaxomicin inhibits spore production in clostridium difficile. Clin Infect Dis 55:S162\u2013S169. doi: 10.1093\/cid\/cis453","journal-title":"Clin Infect Dis"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jhin.2015.01.015","volume":"90","author":"JS Biswas","year":"2015","unstructured":"Biswas JS, Patel A, Otter JA, Wade P, Newsholme W, van Kleef E et al (2015) Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. J Hosp Infect 90:267\u2013270. doi: 10.1016\/j.jhin.2015.01.015","journal-title":"J Hosp Infect"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40261-015-0291-9","volume":"35","author":"H Oshima","year":"2015","unstructured":"Oshima H, Yamazaki T, Benner L, Miki T, Michon I, Wojtkowski T et al (2015) Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and Caucasian subjects. Clin Drug Investig 35:375\u2013384. doi: 10.1007\/s40261-015-0291-9","journal-title":"Clin Drug Investig"},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1128\/AAC.02904-15","volume":"60","author":"A Deshpande","year":"2016","unstructured":"Deshpande A, Hurless K, Cadnum JL, Chesnel L, Gao L, Chan L et al (2016) Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 60:3988\u20133993. doi: 10.1128\/AAC.02904-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1128\/AAC.00845-15","volume":"59","author":"DR Snydman","year":"2015","unstructured":"Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG et al (2015) U.S.-based national sentinel surveillance study for the epidemiology of clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin. Antimicrob Agents Chemother 59:6437\u20136443. doi: 10.1128\/AAC.00845-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR13","doi-asserted-by":"publisher","first-page":"248.e9","DOI":"10.1016\/j.cmi.2014.09.017","volume":"21","author":"J Freeman","year":"2015","unstructured":"Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C et al (2015) Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 21:248.e9\u2013248.e16. doi: 10.1016\/j.cmi.2014.09.017","journal-title":"Clin Microbiol Infect"},{"key":"2802_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jac\/dkt302","volume":"69","author":"JA Leeds","year":"2014","unstructured":"Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A (2014) In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 69:41\u201344. doi: 10.1093\/jac\/dkt302","journal-title":"J Antimicrob Chemother"},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1128\/AAC.00104-11","volume":"55","author":"F Babakhani","year":"2011","unstructured":"Babakhani F, Gomez A, Robert N, Sears P (2011) Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 55:4427\u20134429. doi: 10.1128\/AAC.00104-11","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","volume":"4","author":"J Jin","year":"2008","unstructured":"Jin J, Sklar GE, Oh VMS, Li SC (2008) Factors affecting therapeutic compliance: a review from the patient\u2019s perspective. Ther Clin Risk Manag 4:269\u2013286","journal-title":"Ther Clin Risk Manag"},{"key":"2802_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13017-015-0033-6","volume":"10","author":"M Sartelli","year":"2015","unstructured":"Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV et al (2015) WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg 10:38. doi: 10.1186\/s13017-015-0033-6","journal-title":"World J Emerg Surg"},{"key":"2802_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/imj.13027","volume":"46","author":"JA Trubiano","year":"2016","unstructured":"Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May MLA et al (2016) Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 46:479\u2013493. doi: 10.1111\/imj.13027","journal-title":"Intern Med J"},{"key":"2802_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/IPC.0000000000000181","volume":"23","author":"EH Eiland","year":"2015","unstructured":"Eiland EH, Sawyer AJ, Massie NL (2015) Fidaxomicin use and clinical outcomes for clostridium difficile-associated diarrhea. Infect Dis Clin Pract 23:32\u201335. doi: 10.1097\/IPC.0000000000000181","journal-title":"Infect Dis Clin Pract"},{"key":"2802_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/phar.1451","volume":"34","author":"CA Vargo","year":"2014","unstructured":"Vargo CA, Bauer KA, Mangino JE, Johnston JEW, Goff DA (2014) An antimicrobial stewardship program\u2019s real-world experience with fidaxomicin for treatment of clostridium difficile infection: a case series. Pharmacotherapy 34:901\u2013909. doi: 10.1002\/phar.1451","journal-title":"Pharmacotherapy"},{"key":"2802_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/phar.1479","volume":"34","author":"A Esmaily-Fard","year":"2014","unstructured":"Esmaily-Fard A, Tverdek FP, Crowther DM, Ghantoji SS, Adachi JA, Chemaly RF (2014) The use of fidaxomicin for treatment of relapsed clostridium difficile infections in patients with cancer. Pharmacotherapy 34:1220\u20131225. doi: 10.1002\/phar.1479","journal-title":"Pharmacotherapy"},{"key":"2802_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1128\/AAC.04268-14","volume":"59","author":"S Penziner","year":"2015","unstructured":"Penziner S, Dubrovskaya Y, Press R, Safdar A (2015) Fidaxomicin therapy in critically ill patients with clostridium difficile infection. Antimicrob Agents Chemother 59:1776\u20131781. doi: 10.1128\/AAC.04268-14","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/AAC.01120-13","volume":"57","author":"DS Clutter","year":"2013","unstructured":"Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A (2013) Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 57:4501\u20134505. doi: 10.1128\/AAC.01120-13","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR24","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1128\/AAC.00939-15.Address","volume":"59","author":"JC Gallagher","year":"2015","unstructured":"Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M (2015) Clinical and economic benefits of fidaxomicin compared to vancomycin for clostridium difficile infection. Antimicrob Agents Chemother 59:7007\u20137010. doi: 10.1128\/AAC.00939-15.Address","journal-title":"Antimicrob Agents Chemother"},{"key":"2802_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10096-015-2538-z","volume":"35","author":"S Goldenberg","year":"2016","unstructured":"Goldenberg S, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D et al (2016) The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 35:251\u2013259. doi: 10.1007\/s10096-015-2538-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2802_CR26","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","volume":"31","author":"MM Levy","year":"2003","unstructured":"Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al (2003) 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Crit Care Med 31:1250\u20131256. doi: 10.1097\/01.CCM.0000050454.01978.3B","journal-title":"Crit Care Med"},{"key":"2802_CR27","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie R (1987) A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2802_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archinte.1962.03620240029006","volume":"110","author":"WR McCabe","year":"1962","unstructured":"McCabe WR, Jackson GG (1962) Gram-negative bacteremia I. etiology and ecology. Arch Intern Med 110:847\u2013855. doi: 10.1001\/archinte.1962.03620240029006","journal-title":"Arch Intern Med"},{"key":"2802_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431\u2013455. doi: 10.1086\/651706","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2802_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2334-13-148","volume":"13","author":"MA Miller","year":"2013","unstructured":"Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y et al (2013) Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 13:148\u2013154. doi: 10.1186\/1471-2334-13-148","journal-title":"BMC Infect Dis"},{"key":"2802_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cid\/cis340","volume":"55","author":"MP Bauer","year":"2012","unstructured":"Bauer MP, Hensgens MPM, Miller MA, Gerding DN, Wilcox MH, Dale AP et al (2012) Renal failure and leukocytosis are predictors of a complicated course of clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 55:149\u2013153. doi: 10.1093\/cid\/cis340","journal-title":"Clin Infect Dis"},{"key":"2802_CR32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MAJ.0b013e3181d3cdaa","volume":"339","author":"J Cadena","year":"2010","unstructured":"Cadena J, Thompson GR, Patterson JE, Nakashima B, Owens A, Echevarria K et al (2010) Clinical predictors and risk factors for relapsing clostridium difficile infection. Am J Med Sci 339:350\u2013355","journal-title":"Am J Med Sci"},{"key":"2802_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11605-009-1093-2","volume":"14","author":"H Dudukgian","year":"2010","unstructured":"Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM (2010) C. difficile colitis-predictors of fatal outcome. J Gastrointest Surg 14:315\u2013322. doi: 10.1007\/s11605-009-1093-2","journal-title":"J Gastrointest Surg"},{"key":"2802_CR34","doi-asserted-by":"publisher","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","volume":"9","author":"CN Abou Chakra","year":"2014","unstructured":"Abou Chakra CN, Pepin J, Sirard S, Valiquette L (2014) Risk factors for recurrence, complications and mortality in clostridium difficile infection: a systematic review. PLoS One 9:e98400. doi: 10.1371\/journal.pone.0098400","journal-title":"PLoS One"},{"key":"2802_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jhin.2008.08.012","volume":"70","author":"KW Garey","year":"2008","unstructured":"Garey KW, Sethi S, Yadav Y, Dupont HL (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70:298\u2013304. doi: 10.1016\/j.jhin.2008.08.012","journal-title":"J Hosp Infect"},{"issue":"Suppl 2","key":"2802_CR36","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1093\/cid\/cis499","volume":"55","author":"DW Crook","year":"2012","unstructured":"Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA et al (2012) Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 55(Suppl 2):S93\u2013S103. doi: 10.1093\/cid\/cis499","journal-title":"Clin Infect Dis"},{"key":"2802_CR37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/j.gastro.2008.12.038","volume":"136","author":"MY Hu","year":"2009","unstructured":"Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V et al (2009) Prospective derivation and validation of a clinical prediction rule for recurrent clostridium difficile infection. Gastroenterology 136:1206\u20131214. doi: 10.1053\/j.gastro.2008.12.038","journal-title":"Gastroenterology"},{"key":"2802_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/cid\/cis356","volume":"55","author":"DW Eyre","year":"2012","unstructured":"Eyre DW, Walker AS, Wyllie D, Dingle KE, Grif D, Finney J et al (2012) Predictors of first recurrence of clostridium difficile infection: implications for initial management. Clin Infect Dis 55:77\u201387. doi: 10.1093\/cid\/cis356","journal-title":"Clin Infect Dis"},{"key":"2802_CR39","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.3748\/wjg.14.4338","volume":"14","author":"C Hardt","year":"2008","unstructured":"Hardt C, Berns T, Treder W, Dumoulin FL, Hardt C, Dumoulin FL (2008) Univariate and multivariate analysis of risk factors for severe clostridium difficile -associated diarrhoea: Importance of co-morbidity and serum C-reactive protein. World J Gastroenterol 14:4338\u20134341. doi: 10.3748\/wjg.14.4338","journal-title":"World J Gastroenterol"},{"key":"2802_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1086\/649213","volume":"50","author":"M Miller","year":"2010","unstructured":"Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A et al (2010) Health care \u2013 associated clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194\u2013201. doi: 10.1086\/649213","journal-title":"Clin Infect Dis"},{"key":"2802_CR41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/2003\/723471","volume":"17","author":"CN Andrews","year":"2003","unstructured":"Andrews CN, Raboud J, Frcpc BOK, Frcpc RE, Andrews CN, Raboud J et al (2003) Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department. Can J Gastroenterol 17:369\u2013373","journal-title":"Can J Gastroenterol"},{"key":"2802_CR42","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1086\/653012","volume":"50","author":"V Wilson","year":"2010","unstructured":"Wilson V, Cheek L, Satta G, Walker-bone K, Cubbon M, Citron D et al (2010) Predictors of death after clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis 50:e77\u2013e81. doi: 10.1086\/653012","journal-title":"Clin Infect Dis"},{"key":"2802_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1532-5415.2009.02182.x","volume":"57","author":"ED Cober","year":"2009","unstructured":"Cober ED, Malani PN (2009) Clostridium difficile infection in the \u201coldest\u201d old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 57:659\u2013662. doi: 10.1111\/j.1532-5415.2009.02182.x","journal-title":"J Am Geriatr Soc"},{"key":"2802_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jhin.2011.08.015","volume":"79","author":"MR Welfare","year":"2011","unstructured":"Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB (2011) Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 79:359\u2013363. doi: 10.1016\/j.jhin.2011.08.015","journal-title":"J Hosp Infect"},{"key":"2802_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","volume":"175","author":"EG McDonald","year":"2015","unstructured":"McDonald EG, Milligan J, Frenette C, Lee TC (2015) Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med 175:784\u2013794. doi: 10.1001\/jamainternmed.2015.42","journal-title":"JAMA Intern Med"},{"key":"2802_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1017\/ice.2014.88","volume":"36","author":"A Deshpande","year":"2015","unstructured":"Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Hernandez AV et al (2015) Risk factors for recurrent clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 36:452\u2013460. doi: 10.1017\/ice.2014.88","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2802_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ajg.2012.108","volume":"107","author":"CS Kwok","year":"2012","unstructured":"Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107:1011\u20131019. doi: 10.1038\/ajg.2012.108","journal-title":"Am J Gastroenterol"},{"key":"2802_CR48","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1073\/pnas.1001224107","volume":"108","author":"MC Rea","year":"2011","unstructured":"Rea MC, Dobson A, O\u2019Sullivan O, Crispie F, Fouhy F, Cotter PD et al (2011) Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 108:4639\u20134644. doi: 10.1073\/pnas.1001224107","journal-title":"Proc Natl Acad Sci USA"},{"key":"2802_CR49","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/infdis\/jiv256","volume":"212","author":"BB Lewis","year":"2015","unstructured":"Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC et al (2015) Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212:1656\u20131665. doi: 10.1093\/infdis\/jiv256","journal-title":"J Infect Dis"},{"key":"2802_CR50","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1128\/AAC.02262-13","volume":"58","author":"CM Bassis","year":"2014","unstructured":"Bassis CM, Theriot CM, Young VB (2014) Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to clostridium difficile infection. Antimicrob Agents Chemother 58:2767\u20132774. doi: 10.1128\/AAC.02262-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2802_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s15010-016-0894-y","volume":"44","author":"M Watt","year":"2016","unstructured":"Watt M, McCrea C, Johal S, Posnett J, Nazir J (2016) A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection 44(5):599\u2013606. doi: 10.1007\/s15010-016-0894-y","journal-title":"Infection"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-016-2802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-016-2802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-016-2802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:38:20Z","timestamp":1498336700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-016-2802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,8]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1007\/s10096-016-2802-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,8]]}}}